Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREPS Extension: Pregabalin in Partial Seizures
NCT00143130Phase 3Completed
- Sponsor
- Viatris
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of pregabalin in focal seizures, sponsored by Viatris. Primary endpoint: Reduction in seizure frequency at 18 months. Started Apr 2005; status: completed.
02
Drugs
pregabalin
03
Conditions
focal seizures
Beyond the preview
Go deeper on NCT00143130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143130.